Cargando…

Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial

PURPOSE: The goal of the current study was to identify prognostic factors for disease-free survival (DFS) and overall survival (OS) in high-risk stage II colon cancer. METHODS: The subjects were patients with histologically confirmed stage II colon cancer undergoing R0 resection who met at least one...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Kiichi, Sakamoto, Kazuhiro, Tsuchiya, Takashi, Takahashi, Takao, Ohge, Hiroki, Sato, Toshihiko, Taguri, Masataka, Morita, Satoshi, Sadahiro, Sotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615946/
https://www.ncbi.nlm.nih.gov/pubmed/37903983
http://dx.doi.org/10.1007/s00384-023-04559-7
_version_ 1785129292438437888
author Sugimoto, Kiichi
Sakamoto, Kazuhiro
Tsuchiya, Takashi
Takahashi, Takao
Ohge, Hiroki
Sato, Toshihiko
Taguri, Masataka
Morita, Satoshi
Sadahiro, Sotaro
author_facet Sugimoto, Kiichi
Sakamoto, Kazuhiro
Tsuchiya, Takashi
Takahashi, Takao
Ohge, Hiroki
Sato, Toshihiko
Taguri, Masataka
Morita, Satoshi
Sadahiro, Sotaro
author_sort Sugimoto, Kiichi
collection PubMed
description PURPOSE: The goal of the current study was to identify prognostic factors for disease-free survival (DFS) and overall survival (OS) in high-risk stage II colon cancer. METHODS: The subjects were patients with histologically confirmed stage II colon cancer undergoing R0 resection who met at least one of the following criteria: T4, perforation/penetration, poorly differentiated adenocarcinoma, mucinous carcinoma, and < 12 examined lymph nodes. Patients self-selected surgery alone or a 6-month oral uracil and tegafur plus leucovorin (UFT/LV) regimen. Serum CEA mRNA at ≥ 24 h after surgery and < 2 weeks after registration was also examined as a potential prognostic factor for stage II colon cancer. This study is registered with UMIN-CTR (protocol ID: UMIN000007783). RESULTS: 1880 were included in the analysis to identify prognostic factors for DFS and OS in patients with high-risk stage II colon cancer. In multivariate analyses, gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and postoperative adjuvant chemotherapy (POAC) emerged as significant independent prognostic factors for DFS. Similarly, multivariate analysis showed that age, gender, depth of tumor invasion, perforation/penetration, extent of lymph node dissection, number of examined lymph nodes, and POAC were significant independent prognostic factors for OS. Univariate analyses showed no significant difference in DFS or OS for CEA mRNA-positive and mRNA-negative cases. CONCLUSION: This study showed that gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and lack of use of POAC were significant independent prognostic factors in stage II colon cancer.
format Online
Article
Text
id pubmed-10615946
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106159462023-11-01 Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial Sugimoto, Kiichi Sakamoto, Kazuhiro Tsuchiya, Takashi Takahashi, Takao Ohge, Hiroki Sato, Toshihiko Taguri, Masataka Morita, Satoshi Sadahiro, Sotaro Int J Colorectal Dis Research PURPOSE: The goal of the current study was to identify prognostic factors for disease-free survival (DFS) and overall survival (OS) in high-risk stage II colon cancer. METHODS: The subjects were patients with histologically confirmed stage II colon cancer undergoing R0 resection who met at least one of the following criteria: T4, perforation/penetration, poorly differentiated adenocarcinoma, mucinous carcinoma, and < 12 examined lymph nodes. Patients self-selected surgery alone or a 6-month oral uracil and tegafur plus leucovorin (UFT/LV) regimen. Serum CEA mRNA at ≥ 24 h after surgery and < 2 weeks after registration was also examined as a potential prognostic factor for stage II colon cancer. This study is registered with UMIN-CTR (protocol ID: UMIN000007783). RESULTS: 1880 were included in the analysis to identify prognostic factors for DFS and OS in patients with high-risk stage II colon cancer. In multivariate analyses, gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and postoperative adjuvant chemotherapy (POAC) emerged as significant independent prognostic factors for DFS. Similarly, multivariate analysis showed that age, gender, depth of tumor invasion, perforation/penetration, extent of lymph node dissection, number of examined lymph nodes, and POAC were significant independent prognostic factors for OS. Univariate analyses showed no significant difference in DFS or OS for CEA mRNA-positive and mRNA-negative cases. CONCLUSION: This study showed that gender, depth of tumor invasion, extent of lymph node dissection, number of examined lymph nodes, and lack of use of POAC were significant independent prognostic factors in stage II colon cancer. Springer Berlin Heidelberg 2023-10-31 2023 /pmc/articles/PMC10615946/ /pubmed/37903983 http://dx.doi.org/10.1007/s00384-023-04559-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Sugimoto, Kiichi
Sakamoto, Kazuhiro
Tsuchiya, Takashi
Takahashi, Takao
Ohge, Hiroki
Sato, Toshihiko
Taguri, Masataka
Morita, Satoshi
Sadahiro, Sotaro
Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title_full Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title_fullStr Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title_full_unstemmed Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title_short Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
title_sort prognostic factors in patients with high-risk stage ii colon cancer after curative resection: a post hoc analysis of the jfmc46-1201 trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615946/
https://www.ncbi.nlm.nih.gov/pubmed/37903983
http://dx.doi.org/10.1007/s00384-023-04559-7
work_keys_str_mv AT sugimotokiichi prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT sakamotokazuhiro prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT tsuchiyatakashi prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT takahashitakao prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT ohgehiroki prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT satotoshihiko prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT tagurimasataka prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT moritasatoshi prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial
AT sadahirosotaro prognosticfactorsinpatientswithhighriskstageiicoloncanceraftercurativeresectionaposthocanalysisofthejfmc461201trial